
Quarterly report 2024-Q1
added 05-06-2024
ShockWave Medical Revenue 2011-2025 | SWAV
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue ShockWave Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 730 M | 490 M | 237 M | 67.8 M | 42.9 M | 12.3 M | 1.72 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 730 M | 1.72 M | 226 M |
Quarterly Revenue ShockWave Medical
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 219 M | 186 M | 180 M | 161 M | - | 131 M | 121 M | 93.6 M | - | 65.2 M | 55.9 M | 31.9 M | - | 19.6 M | 10.3 M | 15.2 M | - | 11.3 M | 10 M | 7.27 M | - | 3.6 M | 2.28 M | 1.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 219 M | 1.32 M | 69.8 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Abiomed
ABMD
|
848 M | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.86 | -3.26 % | $ 134 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 307.92 | -1.93 % | $ 8.69 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 45.13 | -2.67 % | $ 6.72 K | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Abbott Laboratories
ABT
|
42 B | $ 125.1 | 1.48 % | $ 218 B | ||
|
Boston Scientific Corporation
BSX
|
16.7 B | $ 92.34 | 0.64 % | $ 136 B | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 2.56 | 8.94 % | $ 95.5 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
OrthoPediatrics Corp.
KIDS
|
205 M | $ 17.7 | -3.46 % | $ 408 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Xtant Medical Holdings
XTNT
|
117 M | $ 0.73 | 4.33 % | $ 97.6 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 14.56 | 0.76 % | $ 1.15 B | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 9.88 | 0.05 % | $ 709 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
4 B | $ 165.15 | 0.78 % | $ 12.4 B | ||
|
Accuray Incorporated
ARAY
|
459 M | $ 1.07 | -3.18 % | $ 110 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
31.4 M | $ 12.81 | -1.23 % | $ 346 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 14.86 | -0.03 % | $ 97.4 M | ||
|
AxoGen
AXGN
|
187 M | $ 30.33 | 1.15 % | $ 1.34 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
CONMED Corporation
CNMD
|
1.31 B | $ 40.78 | 2.33 % | $ 1.26 B | ||
|
Globus Medical
GMED
|
2.52 B | $ 86.83 | -2.31 % | $ 11.8 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 13.41 | -4.56 % | $ 1.03 B | ||
|
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M | ||
|
Alphatec Holdings
ATEC
|
612 M | $ 20.04 | 0.65 % | $ 2.86 B | ||
|
Aethlon Medical
AEMD
|
574 K | $ 3.4 | - | $ 5.31 M | ||
|
Establishment Labs Holdings
ESTA
|
166 M | $ 72.58 | -0.19 % | $ 2.04 B | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 0.92 | -4.72 % | $ 14.8 M | ||
|
Electromed
ELMD
|
64 M | $ 29.74 | 0.64 % | $ 251 M | ||
|
IRadimed Corporation
IRMD
|
73.2 M | $ 96.35 | -1.06 % | $ 1.22 B |